The ESCAPE-NEXT trial evaluated nerinetide for acute ischaemic stroke patients undergoing thrombectomy without prior thrombolysis. Nerinetide showed no significant improvement in functional outcomes or safety concerns, highlighting the need for further research into optimal patient selection and treatment timing.